Clinical Trial Update: A Single Dose Study of LY2605541 in Participants With Liver Impairment [Phase 1]

View source ↗

Summary

Phase 1 single-dose study of LY2605541 in participants with hepatic impairment completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• LY2605541

Snippet

Sponsor: Eli Lilly and Company | Conditions: Healthy Volunteers, Hepatic Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2018-10-19